💊 Orexin Antagonist Next-Day Residual Effect Simulator
This simulation models the residual sedative effect of orexin antagonists on the following day, depending on the dose and time of administration, to help clinicians predict and manage potential side effects.
Bedtime Dose Initiates Plasma Rise
A single bedtime pill starts the whole overnight kinetic story.
- 1–2 h: Typical Tmax (Time to peak plasma level.)
- 1.5/h: Absorption rate (ka) (Fast gut absorption assumed here.)
- 3: Dose forms (Low, standard, and high strengths.)
- OX1R/OX2R: Target receptor (Orexin receptors driving wakefulness.)
Why timing matters
Dose taken late shortens the clearance window before waking.
Dual orexin blockade
Blocking OX1R and OX2R suppresses wake-promoting signaling quickly.
First-pass metabolism
Liver CYP3A4 already starts trimming drug levels on absorption.
A higher dose simply raises the whole overnight curve.
Peak Plasma Concentration During Sleep
Drug level crests roughly one to two hours after dosing.
- ~2 h: Peak occurs (Post-dose plasma maximum, model estimate.)
- Fast: Sedation onset (Sleep induction within 20–30 minutes.)
- +60%: High-dose peak (Relative to standard dose curve.)
- −40%: Low-dose peak (Relative to standard dose curve.)
Peak vs residual
A high peak does not guarantee fast morning clearance.
Sleep architecture
Peak concentration coincides with deepest early-night sleep stages.
Dose-dependent intensity
Higher doses raise peak but also slow later decline.
Bigger doses leave more drug for CYP3A4 to clear later.
Overnight Elimination via CYP3A4
The liver enzyme CYP3A4 steadily breaks the drug down overnight.
- ~8 h: Elimination half-life (Time for plasma level to halve.)
- CYP3A4: Metabolizing enzyme (Dominant hepatic clearance pathway.)
- Many: Interacting drugs (CYP3A4 inhibitors slow elimination further.)
- 7–8 h: Sleep duration typical (Overnight window for clearance.)
Exponential decay
Plasma level falls proportionally, never reaching zero by dawn.
Enzyme variability
Genetics and other medications change individual clearance speed.
Short sleep risk
Waking early cuts elimination time and raises residual drug.
Every extra hour before waking meaningfully lowers residual level.
Morning Plasma Level Depends on Dose and Timing
Wake-time concentration is a tug-of-war between dose and hours slept.
- ≥7 h: FDA guidance (Minimum recommended sleep before waking.)
- Worst case: High dose + short sleep (Combination drives highest residual level.)
- Best case: Low dose + long sleep (Combination drives lowest residual level.)
- Wide: Residual variability (Same dose, different people, different levels.)
Two-lever system
Only dose and timing are adjustable by the prescriber.
Individual variation
Age, weight, and liver function shift the morning number.
Reading the zone
Wake-time concentration lands in a safe, caution, or risk band.
The morning reading is the number that actually matters clinically.
Next-Day Alertness and Driving Risk
Residual sedation is finally checked against real-world task demands.
- Documented: Driving impairment studies (Simulator studies show measurable next-day effects.)
- >55%: High-risk plasma zone (Of standard-dose peak concentration.)
- 30–55%: Caution zone (Task performance may be mildly affected.)
- <30%: Safe zone (Minimal residual impairment expected.)
Beyond subjective sleepiness
Drivers often feel alert despite measurable psychomotor slowing.
Task-specific risk
Driving and machinery operation carry the highest real stakes.
Clinical takeaway
Lowest effective dose taken early protects next-day performance.
Dose and timing together decide whether morning driving is safe.
This simulation models the residual sedative effect of orexin antagonists on the following day, depending on the dose and time of administration, to help clinicians predict and manage potential side effects.
2D · HTML5 Canvas 2D · 60 FPS target · runs fully client-side, no install